FR2397195A1 - Vaccins contre les maladies causees par les paramyxovirus et leur preparation - Google Patents

Vaccins contre les maladies causees par les paramyxovirus et leur preparation

Info

Publication number
FR2397195A1
FR2397195A1 FR7820255A FR7820255A FR2397195A1 FR 2397195 A1 FR2397195 A1 FR 2397195A1 FR 7820255 A FR7820255 A FR 7820255A FR 7820255 A FR7820255 A FR 7820255A FR 2397195 A1 FR2397195 A1 FR 2397195A1
Authority
FR
France
Prior art keywords
components
preparation
diseases caused
vaccines
paramyxovirus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR7820255A
Other languages
English (en)
Other versions
FR2397195B1 (fr
Inventor
Helmut Bachmayer
Peter Reeve
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sandoz AG
Original Assignee
Sandoz AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz AG filed Critical Sandoz AG
Publication of FR2397195A1 publication Critical patent/FR2397195A1/fr
Application granted granted Critical
Publication of FR2397195B1 publication Critical patent/FR2397195B1/fr
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne des vaccins contre les maladies dues aux paramyxovirus et leur préparation. On isole les composants glycoprotéiques des paramyxovirus en traitant ces virus dans un milieu aqueux avec un détergent cationique déterminé, de façon à dissoudre sélectivement ces composants et en séparant les composants solubilisés des particules sous-virales résiduelles ; le mélange des composants glycoprotéiques, en association avec un diluant liquide inerte, constitue le vaccin de l'invention. Le vaccin de l'invention permet en particulier d'obtenir une bonne immunité en l'absence d'effets secondaires indésirables.
FR7820255A 1977-07-13 1978-07-07 Vaccins contre les maladies causees par les paramyxovirus et leur preparation Granted FR2397195A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH872577 1977-07-13

Publications (2)

Publication Number Publication Date
FR2397195A1 true FR2397195A1 (fr) 1979-02-09
FR2397195B1 FR2397195B1 (fr) 1980-10-31

Family

ID=4344006

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7820255A Granted FR2397195A1 (fr) 1977-07-13 1978-07-07 Vaccins contre les maladies causees par les paramyxovirus et leur preparation

Country Status (15)

Country Link
JP (1) JPS5420130A (fr)
AU (1) AU3797378A (fr)
BE (1) BE868916A (fr)
DE (1) DE2829089A1 (fr)
DK (1) DK302978A (fr)
ES (1) ES471615A1 (fr)
FI (1) FI782155A (fr)
FR (1) FR2397195A1 (fr)
GB (1) GB2001326A (fr)
IL (1) IL55119A0 (fr)
IT (1) IT7850237A0 (fr)
NL (1) NL7807367A (fr)
PT (1) PT68275A (fr)
SE (1) SE7807554L (fr)
ZA (1) ZA783998B (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4797474A (en) * 1985-12-11 1989-01-10 Bunge (Australia) Pty. Ltd. Solubilization of protein aggregates

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3014189A1 (de) * 1980-04-14 1981-10-15 Europäisches Laboratorium für Molekularbiologie (EMBL), 6900 Heidelberg Verfahren zur herstellung eines immunogenen membranproteinaggregats von influenza-, parainfluenza- und rhabdo-viren
FI841094A (fi) * 1984-03-19 1985-09-20 Univ Tennesee Research Corp Virusantigen bunden vid en baerare, dess framstaellning och anvaendning.
AU612133B2 (en) * 1987-02-20 1991-07-04 Natinco Nv Production of proteins in active forms
CA1305285C (fr) * 1987-04-21 1992-07-14 Malcolm Roy Brandon Production de proteines actives
EP0295859B1 (fr) * 1987-06-15 1994-11-17 Southern Cross Biotech Pty.Ltd. Préparation de protéines dans les formes actives
AU712213B2 (en) * 1995-09-22 1999-11-04 Connaught Laboratories Limited Parainfluenza virus glycoproteins and vaccines
HUP0302636A3 (en) * 2000-10-02 2008-03-28 Glaxosmithkline Biolog Sa Split enveloped virus preparation
DE10309691B4 (de) * 2003-02-28 2018-10-04 Hans-Knöll-Institut für Naturstoff-Forschung e.V. Gewinnung von löslichen Proteinen aus der Biomasse rekombinanter Mikroorganismen

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2257305A1 (fr) * 1974-01-14 1975-08-08 Sandoz Sa

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2257305A1 (fr) * 1974-01-14 1975-08-08 Sandoz Sa

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CA1978 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4797474A (en) * 1985-12-11 1989-01-10 Bunge (Australia) Pty. Ltd. Solubilization of protein aggregates

Also Published As

Publication number Publication date
GB2001326A (en) 1979-01-31
BE868916A (fr) 1979-01-11
JPS5420130A (en) 1979-02-15
IL55119A0 (en) 1978-09-29
IT7850237A0 (it) 1978-07-11
ES471615A1 (es) 1979-10-01
AU3797378A (en) 1980-01-17
FI782155A (fi) 1979-01-14
SE7807554L (sv) 1979-01-14
PT68275A (fr) 1978-08-01
DK302978A (da) 1979-01-14
NL7807367A (nl) 1979-01-16
DE2829089A1 (de) 1979-02-01
FR2397195B1 (fr) 1980-10-31
ZA783998B (en) 1980-02-27

Similar Documents

Publication Publication Date Title
FR2397195A1 (fr) Vaccins contre les maladies causees par les paramyxovirus et leur preparation
MA42811B1 (fr) Dérivés d'indole monosubstitués ou disubstitués utilisés en tant qu'inhibiteurs de la réplication du virus de la dengue
Mims An analysis of the toxicity for mice of influenza virus: I. Intracerebral toxicity
ES422961A1 (es) Procedimiento para preparar una suspension de virus.
Fuller et al. Association of painful peripheral neuropathy in AIDS with cytomegalovirus infection
ATE163047T1 (de) Selbstständig zusammenfügende replikationsdefekte hybride viruspartikel
GR80853B (en) Kit or device and method for administering gangliosides and derivatives thereof by inhalation and pharmaceutical compositions suitable therefor
DE69628819T2 (de) Kombinationstherapie der hiv-infektion unter verwendung des hiv-protease inhibitors indinavir und des inhibitors der reversen transkriptase 3 tc zusammen mit azt.
WO2005092374A2 (fr) Virus d'herpes simplex recombinant et leurs utilisations
Rinieris et al. Testosterone treatment of depression in two patients with Klinefelter's syndrome.
GB2050833A (en) Pharmaceutical compositions and process for the preparation thereof
Rees et al. Is silica involved in neuritic (senile) plaque formation?
Coryell Intrapatient responses to ECT and tricylic antidepressants.
CO2020010592A2 (es) Forma de dosificación farmacéutica para una emulsión de simeticona y loperamida
Rizvi et al. Obligatory role of macrophages in dengue virus antigen presentation to B lymphocytes
Greiff et al. Influenza: III. rapid alterations in the respiratory rate of embryonated eggs apparently caused by influenza virus toxin
Ilyutchenok et al. Short latency reticulocortical potentials: Effect of muscarinic anticholinergic drugs
US1602748A (en) Sprinkler nozzle
FI930336A (fi) Antineoplastiska, kemoterapeuttiska aemnen, vilka har ett vegetabilisktursprung och en i hoeg grad reducerad toxicitet, och processen foer att preparera dem
Naniche Generalized immunosuppression: individual viruses, intertwined targets
DE903501C (de) Schweisserschutzschild, der mit der Hand gehalten wird
USD105534S (en) Design for a railway car unit
USD144412S (en) Design for a flag
Lennette et al. Propagation of the St. Louis and the Japanese B Encephalitis Viruses in Mouse Testicle
Turhan et al. Sıçan segmenter kemik defekti modelinde trombositten zenginleştirilmiş plazmanın ve demineralize kemik matriksinin kırık iyileşmesi üzerine etkisinin karşılaştırılması

Legal Events

Date Code Title Description
ST Notification of lapse